RT Journal Article
T1 Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.
A1 Montejo, Angel L
A1 Arango, Celso
A1 Bernardo, Miquel
A1 Carrasco, Jose L
A1 Crespo-Facorro, Benidicto
A1 Cruz, Juan J
A1 Del Pino-Montes, Javier
A1 Garcia-Escudero, Miguel A
A1 Garcia-Rizo, Clemente
A1 Gonzalez-Pinto, Ana
A1 Hernandez, Ana I
A1 Martin-Carrasco, Manuel
A1 Mayoral-Cleries, Fermin
A1 Mayoral-van Son, Jaqueline
A1 Mories, M Teresa
A1 Pachiarotti, Isabella
A1 Perez, Jesus
A1 Ros, Salvador
A1 Vieta, Eduard
K1 Antipsychotic
K1 Consensus
K1 Hyperprolactinemia
K1 Neuroleptic
K1 Physical health
AB Hyperprolactinemia is an underappreciated/unknown adverse effects of antipsychotics. The consequences of hyperprolactinemia compromise therapeutic adherence and can be serious. We present the consensus recommendations made by a group of experts regarding the management of antipsychotic-induced hyperprolactinemia. The current consensus was developed in 3 phases: 1, review of the scientific literature; 2, subsequent round table discussion to attempt to reach a consensus among the experts; and 3, review by all of the authors of the final conclusions until reaching a complete consensus. We include recommendations on the appropriate time to act after hyperprolactinemia detection and discuss the evidence on available options: decreasing the dose of the antipsychotic drug, switching antipsychotics, adding aripiprazole, adding dopaminergic agonists, and other type of treatment. The consensus also included recommendations for some specific populations such as patients with a first psychotic episode and the pediatric-youth population, bipolar disorder, personality disorders and the elderly population.
PB Elsevier Inc.
YR 2017
FD 2017-02-17
LK http://hdl.handle.net/10668/10902
UL http://hdl.handle.net/10668/10902
LA en
NO Montejo ÁL, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017 Apr;45:25-34
NO The authors of this article would like to thank Lundbeck andOtsuka for funding this consensus. No Otsuka or Lundbeck employees participated in any of the meetings or teleconferences in whichthese recommendations were drawn up, nor have any Lundbeck orOtsuka employees reviewed this article or made any comments onor suggestions for its content.
DS RISalud
RD Apr 18, 2025